Clinuvel Pharmaceuticals (ASX:CUV) Valuation Rank


ASX:CUV Clinuvel Pharmaceuticals Ltd ASX:CUV
86 GF Score
Price A$10.26
GF Value A$17.73
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Clinuvel Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Clinuvel Pharmaceuticals Valuation Rank Related Terms

ASX:CUV
86GF Score
Clinuvel Pharmaceuticals Ltd ASX:CUV
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?

Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued. The current stock price of A$10.26 is trading 42.1% below its estimated GF Value™ of A$17.73. GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for ASX:CUV:

  • Valuation Rank:
  • GF Value™: A$17.73 vs. price of A$10.26 (42.1% below fair value)
  • GF Score™: 86/100 with 2 warning signs

No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clinuvel Pharmaceuticals Business Description

Address 535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
86GF Score

Get the complete analysis for ASX:CUV

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$10.26
Price
A$17.73
GF Value